Histologic re‑evaluation of a population‑based series of renal cell carcinomas from The Netherlands Cohort Study according to the 2022 ISUP/WHO classification

Odeh, Selena; Samarska, Iryna; Matoso, Andrés; Pol, Jeroen Van De; Baldewijns, Marcella; Kaa, Christina Hulsbergen–van de; Meer, Jaleesa Van Der; Roemen, Guido M.J.M.; Geelkens, Erik; Engeland, Manon van; Hausen, Axel zur; Schouten, Leo J.; Smits, Kim M.

doi:10.3892/ol.2023.13760

Cited by 4 publications

(2 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Odeh et al, re-evaluated renal cell carcinoma according to the 2022 WHO classification in a large cohort of 457 cases and found no discrepancy with the previous diagnoses ( 9 ). A recent study showed that two thirds of tumours which were “unclassifiable eosinophilic RCC” were reclassified based on the newer immunohistochemical markers and contributed to the prognostic outcomes ( 10 ).…”

Section: Discussionmentioning

confidence: 95%

Reclassifying papillary, oncocytic and chromophobe renal tumours based on the 5th who classification 2022

Shaikh,

Mathew

2024

TJPATH

View full text Add to dashboard Cite

Objective: The classification of renal tumors is expanding with the addition of new molecular entities in the 5th World Health Organization classification. Apart from this, the major updates in the definition of papillary renal cell carcinoma are that these tumors are no longer subtyped into type 1 and type 2. In oncocytic tumors, the new molecularly defined renal tumors, emerging and novel entities need to be considered in the diagnosis of oncocytic and chromophobe renal tumors. Material and Methods: This is a retrospective study to review and reclassify papillary, oncocytic, and chromophobe renal tumors based on the new WHO classification and correlate with clinical data, gross, microscopic features, and immunohistochemistry markers. Results: A total of thirteen cases were reviewed and the tumor grade was changed for three out of four cases of papillary renal cell carcinoma and a single case was recategorized and graded. In nine cases of oncocytic and chromophobe renal tumors, the diagnoses were modified in 3 cases. Conclusion: Newly defined molecular renal tumors require advanced immunohistochemistry markers and molecular tests. This poses diagnostic challenges to pathologists practicing in low resource settings where molecular tests are not available.

show abstract

Section: Discussionmentioning

confidence: 95%

Reclassifying papillary, oncocytic and chromophobe renal tumours based on the 5th who classification 2022

Shaikh,

Mathew

2024

TJPATH

View full text Add to dashboard Cite

show abstract

“…To explore the impact of contrast enhanced CTs on our results, we first performed a sensitivity analysis where we excluded patients whose CTs contained contrast ( n = 217, 17%); next we tested whether associations between body composition and pathological tumour features differed by contrast using effect measure modification, and finally, present multivariable models adjusted for contrast. We conducted an exploratory analysis of the potential impact of the tumour grade classification change by performing a probabilistic sensitivity analysis following methods for outcome misclassification 27 based on the concordance between Fuhrman and ISUP grade reported by Odeh et al 28 For methodological details, see supporting information. All statistical tests used a significance level of 0.05.…”

Section: Methodsmentioning

confidence: 99%

Skeletal muscle and visceral adipose radiodensities are pre‐surgical, non‐invasive markers of aggressive kidney cancer

Furberg,

Bradshaw,

Knezevic

et al. 2024

J cachexia sarcopenia muscle

View full text Add to dashboard Cite

IntroductionMost studies on body composition in kidney cancer have been conducted among patients with metastatic disease. Given that aggressive tumours can adversely impact body composition and even non‐metastatic tumours can be aggressive, we evaluated associations between pre‐surgical body composition features and tumour pathological features in patients with non‐metastatic clear cell renal cell cancer (ccRCC).MethodsThe Resolve Cohort consists of 1239 patients with non‐metastatic ccRCC who underwent nephrectomy at Memorial Sloan Kettering Cancer Center between 2000 and 2020. The cross‐sectional areas and radiodensities of skeletal muscle, visceral adipose, and subcutaneous adipose tissues were determined from pre‐surgical computed tomography (CT) scans at the third lumbar vertebrae using Automatica software. Pearson's correlation coefficients describe inter‐relationships among BMI and body composition variables, while odds ratios (OR) and 95% confidence intervals (CI) estimate associations between continuous body composition features (per 1‐standard deviation) and advanced stage (Stage III vs. Stages I–II) and high Fuhrman grade (Grades 3–4 vs. 1–2) from multivariable logistic regression models that considered the potential impact of biological sex, contrast enhanced CTs, and early age at onset of ccRCC.ResultsThe cohort was predominantly male (69%), white (89%), and had a median age of 58. The proportion of patients presenting with advanced stage and high‐grade disease were 31% and 51%, respectively. In models that adjusted for demographics and all body composition variables simultaneously, decreasing skeletal muscle radiodensity (i.e., more fat infiltration) but increasing visceral adipose tissue radiodensity (i.e., more lipid depletion) were associated with advanced tumour features. Per 8.4 HU decrease in skeletal muscle radiodensity, the odds of presenting with advanced stage was 1.61 (95% CI: 1.34–1.93). Per 7.22 HU increase in visceral adipose tissue radiodensity, the odds of presenting with advanced stage was 1.45 (95% CI: 1.22–1.74). Skeletal muscle index (i.e., sarcopenia) was not associated with either tumour feature. Similar associations were observed for Fuhrman grade, a more direct marker of tumour aggressiveness. Associations did not differ by sex, contrast use, or age at onset of ccRCC.ConclusionsLipid infiltrated skeletal muscle, but lipid depleted visceral adipose tissue were independently associated with advanced tumour features in non‐metastatic ccRCC. Findings highlight the importance of evaluating the full range of body composition features simultaneously in multivariable models. Interpreting pre‐surgical CTs for body composition for patients may be a novel and non‐invasive way to identify patients with aggressive renal tumours, which is clinically relevant as renal biopsies are not routinely performed.

show abstract

PET/CT with 18F-PSMA-1007 in Diagnostics of Primary and Recurrent Lesions of Clear-cell Renal Cell Carcinoma in Comparison with 18F-FDG: Prospective Study

Ilyakov,

Pronin,

Parnas

et al. 2024

jour

View full text Add to dashboard Cite

Introduction: Attempts have been made to use various RPs, other than 18F-FDG in the diagnostics of renal cell carcinoma (RCC), with promising results demonstrated by PSMA-specific RPs, in particular 18F-PSMA-1007.A prospective study was conducted at N.N. Blokhin NMRCO to establish capabilities of PET/CT with 18F-FDG and 18F-PSMA-1007 in primary and recurrent ccRCC diagnostics.Material and methods: Forty-eight patients were included in the study, 28 with renal masses and 20 with suspected local recurrence of ccRCC. Biopsy results were available in all patients. All patients underwent PET/CT with 18F-PSMA-1007 and 18F-FDG.Results: Thirty-nine renal neoplasms were identified in 28 patients. 24 of 39 foci (21 patients) were PSMA-positive and 18 of 39 foci (16 patients) were FDG-positive. No false-positive foci were identified. The sensitivity, specificity, positive and negative predictive value in primary RCC were: for 18F-PSMA-1007 — 75, 100, 100 and 85 %, respectively; for 18FDG — 57, 100, 100 and 76 %, respectively. The SUVmax level of 18F-PSMA-1007 exceeded 18FDG in 27 of 28 patients (38 foci); the tumor/background ratio was higher in 16 of 28 patients (24 foci). Tumor thrombosis was detected in 6 patients (PSMA-positive 6 of 6, FDG-positive 5 of 6). PSMA-SUVmax levels in thrombi exceeded 18FDG in all patients, tumor/background ratio in 5 out of 6 patients. Local recurrence was detected in 13 of 20 patients (27 foci). 10 foci in the remaining 7 patients were considered as false positives. No false-negative results were obtained. Sensitivity, specificity, positive and negative predictive value in the diagnosis of local recurrence of ccPCC: 18F-PSMA-1007 — 100, 94, 81 and 100 %, respectively; 18FDG -100, 89, 68 and 100 %, respectively.SUVmax and tumor/background ratio were found to correlate with primary tumor and recurrent node sizes for both RPs.Discussion and conclusions: At the moment, the role of 18F-PSMA-1007 in RCC diagnostics has not been defined. We can note the high efficiency of this RP in the assessment of the primary focus and recurrence of ccRCC, its usage is justified in cases, when routine diagnostic methods do not give an unambiguous answer.The possibilities of 18F-PSMA-1007 in metastatic ccRCC diagnostics are of the greatest interest. A significant prospective material has been collected in our department, which will be the basis for further study of this RP in the diagnostics of metastatic ccRCC.

show abstract

Histologic re‑evaluation of a population‑based series of renal cell carcinomas from The Netherlands Cohort Study according to the 2022 ISUP/WHO classification

Cited by 4 publications

References 66 publications

Reclassifying papillary, oncocytic and chromophobe renal tumours based on the 5<sup>th</sup> who classification 2022

Reclassifying papillary, oncocytic and chromophobe renal tumours based on the 5<sup>th</sup> who classification 2022

Skeletal muscle and visceral adipose radiodensities are pre‐surgical, non‐invasive markers of aggressive kidney cancer

PET/CT with <sup>18</sup>F-PSMA-1007 in Diagnostics of Primary and Recurrent Lesions of Clear-cell Renal Cell Carcinoma in Comparison with <sup>18</sup>F-FDG: Prospective Study

Contact Info

Product

Resources

About